

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number
WO 03/037320 A1

(51) International Patent Classification⁷: **A61K 31/197**,
31/198, 31/7052, 38/00, 31/195, 31/70

(21) International Application Number: **PCT/IB02/04242**

(22) International Filing Date: 15 October 2002 (15.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0126194.0 1 November 2001 (01.11.2001) GB

(71) Applicant (*for all designated States except US*): **NEW TECHNOLOGY RESEARCH LTD.** [GB/GB]; Pasea Estate, Road Town, Tortola (VG).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **RAGGI, Giuseppe** [CH/CH]; Via al Forte, 3, CH-6900 Lugano (CH).

(74) Agent: **FIAMMENGHI-DOMENIGHETTI, Delfina**; Fiammenghi-Fiammenghi, Via San Gottardo, 15, CH-6900 Lugano (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACO-DIETARY PREPARATION HAVING A NUTRITION-SUPPLEMENTING AND NUTRITION-ENHANCING EFFECT

(57) Abstract: A pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect and comprising: a) a hydrolysate of amino acids and/or peptides having a relative molecular mass between 10^2 and 2×10^4 daltons obtained from proteins; b) β -alanine in an amount equal to, or greater than, 0.1% of the aminoacyl total of the hydrolysate of amino acids and/or peptides.

WO 03/037320 A1

Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect

5 The present invention relates to pharmaceutical and/or dietary compositions and/or functional human and/or animal foods capable of promoting a reduction of excess weight, preventing aging processes, and assisting in the treatment of disorders linked thereto: atherosclerosis, hypertension, diabetes, osteoporosis, menopausal syndromes, senile cerebral disorders (Alzheimer's disease, Parkinson's disease, dementias and
10 memory losses), psychophysical stresses, depression, chronic fatigue syndrome, cutaneous and dermal aging (wrinkles, cellulitis, alopecia, et cetera), benign prostate hypertrophy, et cetera.

Free radicals (and the peroxidative processes they induce), together with protein
15 malnutrition (often caused by inefficient digestion of proteins and/or by a reduced efficiency of intestinal absorption of amino acids) and with deficits of vitamins, oligoelements and minerals and vitamin-like factors (for example nucleosides derived from the digestion of nucleic acids), have long been recognized as the primary causes of metabolic and structural alterations (such as excess weight, high plasma levels of
20 cholesterol, triglycerides, glucose, reduced levels of antioxidant defences in plasma and in the various tissues, energy deficits of mitochondria and of cell metabolism, damage to DNA and RNAs) that occur in various situations of psychophysical stress and during aging, as well as during the onset of many disorders correlated to aging such as atherosclerosis, diabetes, hypertension, et cetera (Supplement to "The American Journal
25 of Clinical Nutrition", vol. 53 (No. 1), 1991, p. 189; "Lipid Peroxidation": part II: "Pathological Implications", 1987, Chemistry and Physics of Lipids, vol. 45 (no. 2-4), p. 103; "Undernutrition in elderly people", 1989, Age Ageing, vol. 18, p. 339; "Malnutrition and falls", 1990, Lancet, vol. 336, p. 1447).

30 In order to avoid all these pathological degenerations, the inventor of the present invention has devised a preparation that has marked organoleptic virtues. The invention is in fact constituted by a preparation as described in the accompanying Claim 1.

A description is now given of some preferred embodiments of the preparation according to the invention, chosen among the many available to a person skilled in the art who follows the teachings contained in the accompanying Claim 1.

5

The composition of the preparation according to the invention essentially comprises:

- a hydrolysate of amino acids and/or peptides, with a relative molecular mass between 10^2 and 2×10^4 daltons, obtained by hydrolysis of proteins having a high biological value (for example proteins of milk serum, soybean, eggs, wheat, maize, yeasts, fish, meat, et cetera) with the addition of β -alanine in an amount $\geq 0.1\%$ of the aminoacyl total and preferably between 1 and 3%. Said hydrolysate must receive a further addition of glycine ($\geq 1.5\%$ of the aminoacyl total) and/or glutamine ($\geq 3\%$ of the aminoacyl total and/or taurine ($\geq 0.1\%$ of the amino acyl total) and/or arginine ($\geq 2.1\%$ of the aminoacyl total) if these amino acids are not already present in the above cited amounts.

15

To boost the effects of the preparation according to the invention it is possible to add:

- a hydrolysate of oligonucleotides and/or nucleotides and/or nucleosides, obtained by hydrolysis from ribonucleic and/or deoxyribonucleic acids extracted from yeasts, plants, meat or fish, with a relative molecular mass preferably between 10^2 and 10^4 , optionally with the addition of adenosine (so that the amount of adenine is $\geq 10\%$ of the total of all the nitrogen bases present in the oligonucleotides and/or nucleotides and/or nucleosides of the hydrolysate).

25

- a mixture of protein extracts having a hydrolytic activity, of plant and/or animal and/or bacterial origin (for example extracts of *Aspergillus oryzae* fermented in the presence of rice starch).

30

- a mixture containing D-ribose and/or xylitol.

Furthermore, the preparation according to the invention can contain other components used conventionally, such as for example:

5

- the different species of vitamins and/or vitamin-like products (for example carnitine, creatine, carnosine, homo-carnosine, anserine, betaine, lipoic acid, essential fatty acids of the w-6 and w-3 series, lecithins, inositol, et cetera)

10

- the various species of minerals and oligoelements

- carbohydrates of various kinds (glucose, fructose, saccharose, lactose, arabinose, starches, maltodextrins, et cetera)

15

- indigestible fibres and/or polysaccharides (inulins, pectins, celluloses, cyclodextrins, et cetera)

- extracts of plants and/or spices and/or medicinal plants containing phytosterols, bioflavones, terpenes, essential oils, et cetera.

20

As regards the dosage of the various compounds of the preparation, it can be defined within a wide discretionary range: however, the inventor suggests, for the preparation, a dosage of 0.05 + 5.0 grams of preparation per day per kilogram of body weight of the person taking it, although optimum dosage is between 0.5 and 2.0 grams per day per
25 kilogram of body weight.

As regards the relative dosage of the individual components of the preparation, the inventor suggests to use preferably an amount of said hydrolysate of oligonucleotides and/or nucleotides and/or nucleosides between 1 and 10 mg per day per kg of body
30 weight.

For said mixture of protein extracts having hydrolytic activity of plant and/or animal

origin, the inventor suggests a dosage between 0.01 and 2 grams, but preferably between 0.1 and 0.5 grams, per kg of body weight per day.

For said mixture containing D-ribose and/or xylitol, moreover, the inventor suggests a daily dosage in which the administered amount of D-ribose is 0.1 to 250 mg, but preferably 1 ÷ 25 mg, per kg of body weight, and the amount of xylitol is 0.1 to 1000 mg, but preferably 2 to 100 mg, per kg of body weight. Obviously, the preparation according to the invention can be administered as a single daily dose or split into multiple doses.

The powder and/or granulated forms of the above described components, which are perfectly miscible and usable with each other, are formulated in a composition suitable for oral administration, such as sachets containing powders or granulates; pastilles and dragées; ordinary or effervescent tablets; pasta, rice, crackers, bread, biscuits or other bakery products obtainable by mixing the various active ingredients, in the form of powders and/or granulates, with appropriate food-grade pharmacologically inert excipients, such as simple or complex carbohydrates (food-grade flours of various origin, starches, vegetable fibres of various kinds, and celluloses, chitins or chitosans, pectins, inulins, saccharose, lactose, et cetera); sauces, condiments, creams and/or mayonnaises obtainable by mixing the active ingredients with oils, water, lecithin, natural emulsifiers and any other ingredient normally used in this type of preparation; powdered dispersions for extemporaneous production of milk-beverages and yogurth, beverages of various kinds; appropriately flavoured chewing-gums, et cetera.

A preparation according to the invention can also be used in the cosmetic application-field in the form of a cream, of a gel or the like, via aerosol etc.

Two non-limitative examples of possible formulations according to the present invention are presented hereinafter.

Example 1

A) 100 g of a hydrolysate of amino acids and/or peptides (with a relative molecular

5

mass between 10^2 and 2×10^4) from milk serum proteins, having the following amino acid composition:

Alanine	5.04 g	Leucine	12.096 g	Tyrosine	3.444 g
Arginine	2.184 g	Lysine	9.66 g	Valine	4.704 g
Aspartic acid	10.164 g	Methionine	2.101 g		
Cystine	3.024 g	Phenylalanine	3.276 g		
Glutamine and glutamic acid	15.12 g	Proline	4.368 g		
Glycine	1.512 g	Serine	3.024 g		
Histidine	1.764 g	Threonine	4.452 g		
Isoleucine	4.956 g	Tryptophan	2.100 g		

5 with the addition of

- 4 g glycine
- 6 g glutamine
- 1500 mg β -alanine
- 250 mg taurine

10

+

B) 2 g of a mixture of oligonucleotides, nucleotides and nucleosides (with a relative molecular mass between 2×10^2 and 10×10^3 daltons) obtained by hydrolysis of nucleic acids from yeast, with the addition of 500 mg of adenosine.

15

+

C) 8 g of a mixture of protein extracts having a hydrolytic activity (4 g of protein extract of pineapple stalk rich in bromelain + 4 g of pancreatic protein extract rich in trypsin, chymotrypsin, et cetera)

20

+

D) 5 g of a mixture of D-ribose (1 g) and xylitol (4 g).

Example 2

A) 127.25 g of a mixture of protein and nucleotide hydrolysates, protein extracts having proteolytic activity and D-ribose and xylitol as in example 1 A) + 1 B) + 1 C) +
 5 1 D)

+

B) a mixture of vitamins, vitamin-like factors, minerals and oligonucleotides, carbohydrates and fibres constituted by:

10

Inulins and pectins	8 g	B6	8 mg	Zn	20 mg	Phosphor	200 mg
Vitamin A	2 mg	B12	200 µg	Cu	100 µg	Sodium	300 mg
Vitamin E	100 mg	Biotin	200 µg	Boron	100 µg	Maltodextrins	22 g
Vitamin C	100 mg	Folic acid	200 µg	Cr	100 µg	w-6 and w-3 essential fatty acids	4 g
Vitamin D	12 µg	Inositol	400 mg	Vanadium	40 µg	Lecithins	4 g
Vitamin B1	4 mg	Ca	200 mg	Molybdenum	100 µg	Creatine	4 g
Vitamin B2	4 mg	Magnesium	200 mg	Iodine	100 µg	Lipoic acid	200 mg
B3 nicotinamide	60 mg	Potassium	600 mg	Iron	4 mg		
B5 pantothenic acid	20 mg	Chloride	300 mg	Mn	10 mg		

In order to study the pharmacological and/or dietary characteristics of the composition according to the present invention, a series of experimental tests on rats and clinical tests in man was conducted.

- 5 As regards experimental tests on rats, 60 male rats, divided into 5 groups of 12 animals each, were used. Each group of animals was subjected to a dietary regimen as listed in Table I according to times and methods indicated in Table II.

At the end of the treatments, various body composition parameters were measured
10 (initial and final weight, percentage compositions of H₂O, proteins and fats in the body, variation of levels of deposit of epididymal and perirenal fats; Table III; blood levels of total cholesterol, HDL cholesterol, triglycerides and glucose (Table III); levels of lipoperoxides (MDA) in plasma, liver, brain and heart, hepatic content of reduced glutathione (GSH), and consumption of hepatocellular oxygen and renal levels of 8-
15 oxo-d-guanosine (Table IV).

Experimental data listed in Tables III and IV show that:

- 1) Treatment for 84 days with a diet rich in fats with respect to the standard diet
20 induced a dramatic and significant increase in body weight and fat content of the animal, with a decrease in protein masses and in the state of hydration of tissues. There was also a significant increase in blood levels of triglycerides, cholesterol and glucose. Levels of lipoperoxides in plasma and in the various tested tissues were also increased (a clear indicator of reduced efficiency of antioxidant defences!), and there was also a
25 dramatic decrease in liver content of reduced glutathione (further confirmation of the drop in antioxidant defences!). There was also a reduction in the consumption of hepatocellular oxygen (an indicator of reduced energy efficiency of mitochondrial functions!) and a considerable renal increase in 8-oxo-d-guanosine (an indicator of structural and functional damage to nuclear and/or mitochondrial DNA). All these forms
30 of damage indicated a loss of tissue functionality and predisposition to accelerated aging and to the onset of the dysmetabolic disorders correlated thereto (atherosclerosis, diabetes, hypertension, et cetera).

2) Administration of restricted-calorie diets constituted by milk serum proteins, either untreated (MSP) or hydrolysed (HMSP), was capable of producing a modest preventative effect on the onset of these metabolic-functional alterations.

3) Administration of restricted-calorie diets constituted by hydrolysates of milk serum protein plus the supplements as listed in example 1 of the present invention (HMSP+I) was instead capable of producing a considerable and surprising synergistic effect in:

- facilitating reduction of excess body weight
- increasing lean protein mass and decreasing excess accumulated body fat
- facilitating tissue hydration
- improving antioxidant defences in plasma and in the various tissues
- improving the energy-functional efficiency of the mitochondrion
- reducing damage and mutations affecting nuclear and/or mitochondrial DNA

These therapeutic benefits, obtainable by administering the protein hydrolysates with the addition of the various supplements claimed in the invention, are always significantly greater than the sum of the benefits obtainable by administering separately the protein fractions alone (untreated or hydrolysed, or as the various individual components of the integrated mixture).

In human clinical tests, several groups of overweight individuals, both healthy and affected by one or more of the many dysmetabolic disorders often correlated to aging and/or excess weight (atherosclerosis, diabetes, hypertension, cerebral-degenerative disorders such as Alzheimer's disease, senile dementias, memory loss, et cetera, osteoporosis and menopausal syndromes, states of psychophysical stress, chronic fatigue syndrome, skin aging, wrinkles, cellulite, alopecia, et cetera, benign prostate hypertrophy, et cetera) were subjected to a dietary treatment with the mixture formulated according to the invention as described in example 2. The doses of the mixture and the administration times varied according to the groups being treated and

the extent of the initial excess weight.

In all the clinical studies that were conducted, the beneficial and therapeutic effects obtainable by administering the mixtures formulated according to the invention as listed
5 in example 2 were always been found highly significant in reducing excess weight and improving aging predictive indices, in improving antioxidant defences in plasma (evaluated by monitoring the levels of MDA), in reducing damage to nuclear and/or mitochondrial DNA (evaluated by monitoring 8-oxo-d-guanosine in cells of the mucous membrane of the mouth and/or in urine), and in improving the various tested clinical
10 parameters.

These beneficial aspects observable by administering the mixture formulated completely according to the invention were always been far greater than the effects obtainable by administering the various components (individually or in partial
15 association) that constitute the formulated mixture.

The beneficial and therapeutic effects obtained by administering the mixture formulated according to the present invention also proved themselves capable of increasing and synergistically combining the therapeutic benefits obtainable with the drugs normally
20 used in the various tested disorders; hence the evidence of a possible additional benefit of the use of these supplements: their synergistic effects in assisting the therapeutic action of drugs normally in use in the various disorders cited above.

TABLE I: Percentage composition of experimental diets

Components	Obesity-inducing diet		Restricted-calorie diets		
	Standard diet*	Fat-rich diet	MSP	HMSP	HMSP + supplements as listed in Example 1
Standard diet	100.0	60.0	=	=	=
Milk serum proteins (MSP)			40		
Hydrolysed proteins from milk serum (HMSP)				40	
HMSP + supplements as listed in Example 1					50
Starch			35.3	35.3	25.3
Saccharose			10	10	10
Lard + hydrogenated soya oil = (1+3)		40			
Soya oil			5	5	5
Cellulose			5	5	5
Mixture of minerals			3.5	3.5	3.5
Mixture of vitamins			1.0	1.0	1.0
Choline bitartrate			0.2	0.2	0.2
The standard diet is constituted by: casein (20%); starch (55.3%); saccharose (10%); soya oil (5%); cellulose (5%); mixture of minerals (3.5%); mixture of vitamins (1%); choline bitartrate (0.2%).					

Table II: Experimental protocol

(day)				
0	28	56	84	112
Standard diet (12 rats)				
Fat-rich diet (28 rats)			MSP diet (12 rats)	
Fat-rich diet (48 rats)			HMSP diet (12 rats)	
Fat-rich diet (48 rats)			HMSP+S diet (12 rats)	

1st group, standard diet: sacrificed on day 84

2nd group, fat-rich diet (FR): sacrificed on day 84

3rd group, FR diet + MSP diet: sacrificed on day 112

4th group, FR diet + HMSP diet: sacrificed on day 112

5th group, FR diet + HMSP+S diet: sacrificed on day 112

Table III: Evaluation of the various body composition parameters and blood levels of glucose, cholesterol and triglycerides in rats subjected to the various reference diets and to restricted-calorie diets.

	Reference diets		Restricted-calorie diets		
	Standard diet	Fat-rich diet	Serum proteins (MSP)	Hydrolysed milk serum proteins (HMSP)	HMSP + supplements as listed in Example 1 (HMSP + S)
Initial body weight (g)	93.0	94.4	474.4	478.6	476.4
Final body weight (g)	391.5	476.2	438.4	432.4	408.5
Daily weight gain or loss (g/day)	+3.5	+4.5	-1.2	-1.6	-2.4
Epididymal fat content (g/100 g of body weight)	2.16	3.44	3.22	2.98	2.61
Perirenal fat content (g/100 g of body weight)	2.61	4.42	3.90	3.75	3.02
% H ₂ O content of carcasses	58.4	51.2	52.6	53.5	56.0
% protein content of carcasses	19.4	16.9	17.6	18.1	19.1
% fat content of carcasses	18.0	27.4	25.1	23.6	19.7
Blood glucose (mmol/litre)	9.87	10.54	11.26	10.68	9.21
Blood triglycerides (mmol/litre)	1.07	1.54	1.39	1.17	0.86
Total blood cholesterol (mmol/litre)	1.68	1.94	2.24	2.12	1.78
Blood HDL cholesterol (mmol/litre)	0.99	1.07	1.24	1.15	1.05

Table IV: Levels of lipoperoxides as nmols of malonyldialdehyde (MDA) per g of tissue or per ml of plasma, variations in hepatocellular oxygen consumption and hepatic levels of reduced glutathione (GSH), and variations in kidney levels of 8-oxo-d-guanosine in rats subjected to the various diets.

	Reference diets		Restricted-calorie diets		
	Standard diet	Fat-rich diet	Milk serum proteins (MSP)	Hydrolysed milk serum proteins (HMSP)	HMSP + supplements as listed in example I (HMSP+I)
*plasma MDA	2.5	5.1	5.0	4.6	3.4
*liver MDA	25.6	44.8	41.5	36.8	28.9
*brain MDA	55.4	108.5	102.4	98.5	76.5
*heart MDA	24.8	45.6	40.2	36.8	29.8
**hepatocellular oxygen consumption $\mu\text{mols O}_2/\text{min per } 10^7 \text{ cells}$)	276.4	194.5	206.8	228.4	259.3
**hepatic GSH nmols/ 10^5 cells	36.1	22.4	28.0	32.2	40.8
***Kidney levels of 8-oxo-7,8 dehydro-2'-deoxyguanosine expressed as ratio with respect to d-guanosine ($\times 10^5$)	2.87	3.65	3.56	3.48	3.08

* MDA is dosed according to the method of K. Yogi et al., 1982 "Lipid Peroxides in Biology and Medicine", Academic Press, New York, pages 324-340

** O_2 consumption and levels of GSH in liver are dosed according to the method of T. M. Hagen et al., 1999, FASEB J., vol. 13, pages 411-418

*** the kidney level of 8-oxo-d-guanosine is dosed according to the method of M. Karbownik et al., 2001, Mutation Res., 474, pages 87-92.

CLAIMS

1. A pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect, characterized in that it comprises:

5

a) a hydrolysate of amino acids and/or peptides having a relative molecular mass between 10^2 and 2×10^4 daltons obtained from proteins;

10

b) β -alanine in an amount equal to, or greater than, 0.1% of the aminoacyl total of said hydrolysate of amino acids and/or peptides.

2. The preparation according to claim 1, furthermore comprising glycine in an amount equal to, or greater than, 1.5% of the aminoacyl total of said hydrolysate of amino acids and/or peptides.

15

3. The preparation according to one of the preceding claims, furthermore comprising glutamine in an amount equal to, or greater than, 3% of the aminoacyl total of said hydrolysate of amino acids and/or peptides.

20

4. The preparation according to one of the preceding claims, furthermore comprising taurine in an amount equal to, or greater than, 0.1% of the aminoacyl total of said hydrolysate of amino acids and/or peptides.

25

5. The preparation according to one of the preceding claims, furthermore comprising arginine in an amount equal to, or greater than, 2.1% of the aminoacyl total of said hydrolysate of amino acids and/or peptides.

6. The preparation according to claim 1, furthermore comprising:

30

- a hydrolysate of oligonucleotides and/or nucleotides and/or nucleosides obtained by hydrolysis from ribonucleic and/or deoxyribonucleic acids extracted from yeasts, plants, meat or fish, having a relative molecular mass between 10^2 and 10^4 , optionally

15

with the addition of adenosine so that the amount of adenine is $\geq 10\%$ of the total of all nitrogenous bases present in the oligonucleotides and/or nucleotides and/or nucleosides of the hydrolysate, and/or

- 5 - a mixture of protein extracts having a hydrolytic activity of plant and/or animal and/or bacterial origin, and/or
- a mixture containing d-ribose and/or xylitol.
- 10 7. The preparation according to one of the preceding claims, having the consistency of powder or granulate.
8. The preparation according to the preceding claims 1 or 2, packaged in the form of tablets.

15

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/IB 02/04242

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/197 A61K31/198 A61K31/7052 A61K38/00 A61K31/195
A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 154 397 A (ERBA CARLO SPA) 11 May 1973 (1973-05-11) claim 1	1-3,5,7
X	US 5 587 399 A (LIEBRECHT JEFFREY W ET AL) 24 December 1996 (1996-12-24) claim 1	1-5,7
Y	WO 95 31114 A (SCIENT HOSPITAL SUPPL INT LTD ;SMITH STEPHEN LEYLAND (GB); GRIGOR) 23 November 1995 (1995-11-23) claims 1,12 page 5, paragraphs 1,3,5	1-8
Y	EP 0 891 719 A (NUTRICIA NV) 20 January 1999 (1999-01-20) claims 4,7,10	1-8
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

14 January 2003

Date of mailing of the international search report

12/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Beranová, P

INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/IB 02/04242

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 656 608 A (SCHNEIDER HEINZ ET AL) 12 August 1997 (1997-08-12) claims 7,9 ----	1-8
Y	US 5 925 377 A (AYRES JAMES R ET AL) 20 July 1999 (1999-07-20) claim 11 ----	6-8
Y	US 5 569 458 A (GREENBERG MIKE) 29 October 1996 (1996-10-29) claim 1 ----	6-8
Y	WO 99 65476 A (BIOENERGY INC ;ST CYR JOHN (US); JOHNSON CLARENCE A (US)) 23 December 1999 (1999-12-23) claims 9,10 page 6, line 1 - line 2 ----	6-8
Y	US 5 626 883 A (PAUL STEPHEN M) 6 May 1997 (1997-05-06) claim 19 column 9, line 34 -----	6-8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 02/04242

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1 and 6 relate to an extremely large number of possible compounds/products ("hydrolysate of amino acids/peptides", "hydrolysate of oligonucleotides/nucleotides/nucleosides" and "protein extract having a hydrolytic activity"). Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds/products claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds/products mentioned in Examples.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal application No

PCT/IB 02/04242

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
FR 2154397	A	11-05-1973	IT 945910 B	10-05-1973
			FR 2154397 A1	11-05-1973
US 5587399	A	24-12-1996	US 5550146 A	27-08-1996
			AU 679020 B2	19-06-1997
			AU 5599194 A	19-07-1994
			CA 2143420 A1	07-07-1994
			DE 69331528 D1	14-03-2002
			DE 69331528 T2	31-10-2002
			EP 0675725 A1	11-10-1995
			ES 2173109 T3	16-10-2002
			WO 9414458 A1	07-07-1994
WO 9531114	A	23-11-1995	AT 175075 T	15-01-1999
			AU 683159 B2	30-10-1997
			AU 2451295 A	05-12-1995
			CA 2190103 A1	23-11-1995
			DE 69507026 D1	11-02-1999
			EP 0758852 A1	26-02-1997
			FI 964535 A	09-01-1997
			WO 9531114 A1	23-11-1995
			NO 964815 A	30-12-1996
			NZ 285426 A	24-09-1998
EP 0891719	A	20-01-1999	EP 0891719 A1	20-01-1999
			AU 8465898 A	10-02-1999
			EP 1001685 A1	24-05-2000
			HK 1028324 A3	16-02-2001
			JP 2001510145 T	31-07-2001
			WO 9903365 A1	28-01-1999
			US 2002142025 A1	03-10-2002
US 5656608	A	12-08-1997	AT 191615 T	15-04-2000
			AU 710527 B2	23-09-1999
			AU 4879596 A	11-09-1996
			BR 9607336 A	25-11-1997
			CA 2210499 A1	29-08-1996
			CN 1175887 A	11-03-1998
			CZ 9702667 A3	18-03-1998
			DE 69607750 D1	18-05-2000
			DE 69607750 T2	31-08-2000
			DK 810829 T3	28-08-2000
			WO 9625861 A1	29-08-1996
			EP 0810829 A1	10-12-1997
			ES 2145997 T3	16-07-2000
			FI 972744 A	22-08-1997
			HU 9800049 A2	28-05-1998
			JP 11501301 T	02-02-1999
			NO 973884 A	17-10-1997
			PL 321238 A1	24-11-1997
			PT 810829 T	31-08-2000
US 5925377	A	20-07-1999	NONE	
US 5569458	A	29-10-1996	NONE	
WO 9965476	A	23-12-1999	US 6159942 A	12-12-2000
			AU 4575299 A	05-01-2000

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/04242

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9965476	A	CA 2334415 A1	23-12-1999
		CN 1306431 T	01-08-2001
		EP 1087779 A2	04-04-2001
		JP 2002518321 T	25-06-2002
		WO 9965476 A2	23-12-1999
		US 6218366 B1	17-04-2001
		US 6429198 B1	06-08-2002
US 5626883	A	AU 2384695 A	10-11-1995
	06-05-1997	WO 9528084 A1	26-10-1995